BlackRock Fund Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

BlackRock Fund Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$502M	Buy	6,818,014 +555,138	+9%	+$45.2M	0.09%	202
2016 Q3	$546M	Buy	6,262,876 +234,950	+4%	+$22.2M	0.11%	163
2016 Q2	$519M	Buy	6,027,926 +175,498	+3%	+$15.2M	0.11%	160
2016 Q1	$465M	Buy	5,852,428 +416,837	+8%	+$37.7M	0.11%	176
2015 Q4	$684M	Sell	5,435,591 -276,878	-5%	-$33.4M	0.16%	99
2015 Q3	$595M	Buy	5,712,469 +158,758	+3%	+$20.4M	0.15%	96
2015 Q2	$686M	Sell	5,553,711 -750,894	-12%	-$94.6M	0.16%	86
2015 Q1	$744M	Buy	6,304,605 +515,366	+9%	+$61.7M	0.18%	85
2014 Q4	$688M	Buy	5,789,239 +180,714	+3%	+$20.4M	0.17%	94
2014 Q3	$630M	Sell	5,608,525 -182,528	-3%	-$17.4M	0.18%	80
2014 Q2	$548M	Sell	5,791,053 -94,471	-2%	-$6.62M	0.15%	103
2014 Q1	$416M	Buy	5,885,524 +430,553	+8%	+$34.1M	0.12%	134
2013 Q4	$405M	Buy	5,454,971 +665,401	+14%	+$46.3M	0.12%	128
2013 Q3	$363M	Sell	4,789,570 -2,163,705	-31%	-$172M	0.12%	130
2013 Q2	$557M	Buy	+6,953,275	New	+$512M	0.2%	72

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's VRTX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 8.9% in Q4 2016, buying an estimated $45.2M and bringing the position to 6,818,014 shares worth $502M. The position accounts for 0.09% of the portfolio, ranked #202.

BlackRock Fund Advisors first reported a position in VRTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $744M in Q1 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

BlackRock Fund Advisors held 6,818,014 shares of Vertex Pharmaceuticals worth $502M as of Q4 2016.
BlackRock Fund Advisors bought 555,138 Vertex Pharmaceuticals shares in Q4 2016, an estimated $45.2M.
Vertex Pharmaceuticals made up 0.09% of BlackRock Fund Advisors's portfolio in Q4 2016, its #202 holding.
BlackRock Fund Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Vertex Pharmaceuticals position peaked at $744M in Q1 2015.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.